Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacterial Proteins | 10 | 2020 | 474 | 1.920 |
Why?
|
| Photoreceptors, Microbial | 11 | 2020 | 11 | 1.850 |
Why?
|
| Photochemical Processes | 9 | 2020 | 15 | 1.840 |
Why?
|
| Nostoc | 8 | 2020 | 8 | 1.760 |
Why?
|
| Phytochrome | 7 | 2015 | 7 | 1.490 |
Why?
|
| Protein Kinases | 2 | 2014 | 143 | 0.860 |
Why?
|
| Kinetics | 11 | 2020 | 538 | 0.590 |
Why?
|
| Synechocystis | 2 | 2014 | 3 | 0.590 |
Why?
|
| Cephalosporins | 2 | 2010 | 18 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 2 | 2012 | 496 | 0.560 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 29 | 0.460 |
Why?
|
| Cross Infection | 2 | 2003 | 35 | 0.430 |
Why?
|
| Light | 3 | 2019 | 117 | 0.420 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2012 | 2 | 0.410 |
Why?
|
| Daptomycin | 1 | 2012 | 6 | 0.410 |
Why?
|
| Pigments, Biological | 1 | 2011 | 7 | 0.400 |
Why?
|
| Bacterial Infections | 1 | 2010 | 54 | 0.340 |
Why?
|
| Synthetic Biology | 2 | 2017 | 2 | 0.280 |
Why?
|
| Intensive Care Units | 2 | 2004 | 46 | 0.270 |
Why?
|
| Color | 4 | 2014 | 22 | 0.250 |
Why?
|
| Mutation | 3 | 2012 | 820 | 0.230 |
Why?
|
| Sepsis | 1 | 2004 | 81 | 0.230 |
Why?
|
| CD8 Antigens | 1 | 2003 | 10 | 0.220 |
Why?
|
| Cephalosporin Resistance | 1 | 2003 | 3 | 0.220 |
Why?
|
| Citrobacter freundii | 1 | 2003 | 2 | 0.220 |
Why?
|
| CD4 Antigens | 1 | 2003 | 18 | 0.220 |
Why?
|
| Ceftriaxone | 1 | 2003 | 6 | 0.220 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2003 | 18 | 0.220 |
Why?
|
| Glycoside Hydrolases | 1 | 2023 | 4 | 0.220 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2003 | 13 | 0.220 |
Why?
|
| Patient Isolation | 1 | 2003 | 1 | 0.220 |
Why?
|
| Gloves, Protective | 1 | 2003 | 2 | 0.220 |
Why?
|
| Disinfection | 1 | 2003 | 10 | 0.220 |
Why?
|
| Zinc | 1 | 2003 | 57 | 0.210 |
Why?
|
| Infection Control | 1 | 2003 | 31 | 0.210 |
Why?
|
| Hand Disinfection | 1 | 2003 | 35 | 0.210 |
Why?
|
| Nanostructures | 1 | 2023 | 62 | 0.200 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2012 | 10 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2003 | 91 | 0.200 |
Why?
|
| Bathroom Equipment | 1 | 2022 | 3 | 0.200 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 139 | 0.200 |
Why?
|
| Rhizosphere | 1 | 2021 | 2 | 0.190 |
Why?
|
| Microtechnology | 1 | 2021 | 4 | 0.190 |
Why?
|
| Brachypodium | 1 | 2021 | 6 | 0.190 |
Why?
|
| Pseudomonas | 1 | 2021 | 13 | 0.190 |
Why?
|
| Protein Conformation | 2 | 2017 | 250 | 0.190 |
Why?
|
| Plant Roots | 1 | 2021 | 46 | 0.190 |
Why?
|
| Molecular Imaging | 1 | 2021 | 35 | 0.190 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2023 | 10 | 0.180 |
Why?
|
| Spectrum Analysis | 3 | 2017 | 29 | 0.180 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2018 | 4 | 0.160 |
Why?
|
| Nucleosides | 1 | 2018 | 6 | 0.160 |
Why?
|
| Oligonucleotides | 1 | 2018 | 27 | 0.150 |
Why?
|
| Photochemistry | 2 | 2017 | 10 | 0.150 |
Why?
|
| DNA Replication | 1 | 2018 | 49 | 0.150 |
Why?
|
| Cyanobacteria | 2 | 2015 | 18 | 0.150 |
Why?
|
| Rhodobacter capsulatus | 1 | 2017 | 2 | 0.150 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2017 | 5 | 0.150 |
Why?
|
| Microfluidics | 1 | 2017 | 12 | 0.150 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2017 | 16 | 0.150 |
Why?
|
| Mutation, Missense | 2 | 2015 | 67 | 0.140 |
Why?
|
| Temperature | 1 | 2017 | 207 | 0.140 |
Why?
|
| Humans | 12 | 2022 | 26842 | 0.130 |
Why?
|
| Isomerism | 2 | 2012 | 12 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-gamma | 1 | 2015 | 1 | 0.120 |
Why?
|
| Female | 9 | 2015 | 14462 | 0.120 |
Why?
|
| Photic Stimulation | 1 | 2015 | 67 | 0.120 |
Why?
|
| Male | 8 | 2015 | 12871 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2014 | 63 | 0.110 |
Why?
|
| Cysteine | 1 | 2014 | 67 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2012 | 1090 | 0.110 |
Why?
|
| Length of Stay | 2 | 2004 | 215 | 0.110 |
Why?
|
| Body Composition | 1 | 2015 | 260 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2012 | 6 | 0.100 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 13 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 544 | 0.100 |
Why?
|
| Sweet Syndrome | 1 | 2012 | 1 | 0.100 |
Why?
|
| Lipodystrophy | 1 | 2012 | 6 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 43 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2012 | 30 | 0.100 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 80 | 0.100 |
Why?
|
| Adolescent | 4 | 2015 | 2957 | 0.090 |
Why?
|
| Middle Aged | 3 | 2010 | 6818 | 0.090 |
Why?
|
| Child | 3 | 2015 | 2146 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2012 | 844 | 0.090 |
Why?
|
| Fever of Unknown Origin | 1 | 2010 | 2 | 0.090 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2010 | 9 | 0.090 |
Why?
|
| Pneumonia, Bacterial | 1 | 2010 | 18 | 0.090 |
Why?
|
| Incidence | 1 | 2012 | 545 | 0.090 |
Why?
|
| Neutropenia | 1 | 2010 | 35 | 0.090 |
Why?
|
| Urinary Tract Infections | 1 | 2010 | 39 | 0.090 |
Why?
|
| United States | 2 | 2015 | 2031 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2010 | 276 | 0.080 |
Why?
|
| Spectrophotometry | 2 | 2019 | 34 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 205 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 650 | 0.080 |
Why?
|
| Amino Acid Motifs | 2 | 2012 | 66 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 283 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2012 | 441 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 674 | 0.070 |
Why?
|
| Young Adult | 2 | 2015 | 2582 | 0.070 |
Why?
|
| Infant | 1 | 2010 | 957 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 1926 | 0.060 |
Why?
|
| Vancomycin Resistance | 1 | 2005 | 4 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2005 | 7 | 0.060 |
Why?
|
| APACHE | 1 | 2004 | 4 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2005 | 702 | 0.060 |
Why?
|
| Patient Admission | 1 | 2004 | 28 | 0.060 |
Why?
|
| DNA | 2 | 2017 | 365 | 0.060 |
Why?
|
| Risk | 1 | 2004 | 133 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 213 | 0.060 |
Why?
|
| Critical Illness | 1 | 2004 | 65 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2004 | 146 | 0.060 |
Why?
|
| Comorbidity | 1 | 2005 | 252 | 0.060 |
Why?
|
| Calorimetry | 1 | 2003 | 12 | 0.060 |
Why?
|
| Phosphoserine | 1 | 2003 | 10 | 0.060 |
Why?
|
| Protein Folding | 1 | 2003 | 47 | 0.060 |
Why?
|
| Dipeptides | 1 | 2003 | 22 | 0.060 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2003 | 43 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2003 | 57 | 0.060 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2003 | 55 | 0.060 |
Why?
|
| Dimerization | 1 | 2003 | 75 | 0.060 |
Why?
|
| Sequence Alignment | 1 | 2003 | 110 | 0.050 |
Why?
|
| Protein Structure, Secondary | 1 | 2003 | 130 | 0.050 |
Why?
|
| Maryland | 1 | 2003 | 7 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2023 | 54 | 0.050 |
Why?
|
| Medical Staff, Hospital | 1 | 2003 | 21 | 0.050 |
Why?
|
| Critical Care | 1 | 2003 | 48 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 25 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 446 | 0.050 |
Why?
|
| Phycocyanin | 2 | 2013 | 2 | 0.050 |
Why?
|
| Phycobilins | 2 | 2013 | 2 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 66 | 0.050 |
Why?
|
| Probability | 1 | 2003 | 75 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2003 | 46 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 44 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2003 | 75 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 204 | 0.050 |
Why?
|
| Fluoresceins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2004 | 859 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 186 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2003 | 560 | 0.050 |
Why?
|
| Aerosols | 1 | 2022 | 41 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 274 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 408 | 0.050 |
Why?
|
| Risk Factors | 2 | 2005 | 2010 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1036 | 0.050 |
Why?
|
| Water | 1 | 2022 | 131 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2004 | 1216 | 0.050 |
Why?
|
| Soil Microbiology | 1 | 2021 | 85 | 0.050 |
Why?
|
| Aged | 1 | 2010 | 5166 | 0.040 |
Why?
|
| Adult | 2 | 2010 | 7382 | 0.040 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2018 | 1 | 0.040 |
Why?
|
| Organophosphorus Compounds | 1 | 2018 | 5 | 0.040 |
Why?
|
| Artificial Cells | 1 | 2017 | 2 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2012 | 263 | 0.040 |
Why?
|
| Ferredoxins | 1 | 2017 | 5 | 0.040 |
Why?
|
| Guanine | 1 | 2017 | 25 | 0.040 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2017 | 35 | 0.040 |
Why?
|
| Sulfur | 1 | 2017 | 33 | 0.040 |
Why?
|
| Nanotechnology | 1 | 2017 | 67 | 0.040 |
Why?
|
| Vibration | 1 | 2017 | 78 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 211 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 354 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2015 | 100 | 0.030 |
Why?
|
| Bile Pigments | 1 | 2013 | 1 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2015 | 130 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2017 | 273 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2015 | 229 | 0.030 |
Why?
|
| Quantum Theory | 1 | 2013 | 19 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 364 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 386 | 0.030 |
Why?
|
| Consanguinity | 1 | 2012 | 5 | 0.030 |
Why?
|
| Turkey | 1 | 2012 | 9 | 0.030 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 7 | 0.030 |
Why?
|
| Fetal Death | 1 | 2012 | 21 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 12 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 667 | 0.030 |
Why?
|
| Siblings | 1 | 2012 | 23 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2012 | 66 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2012 | 11 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 22 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 78 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2012 | 37 | 0.020 |
Why?
|
| Psoriasis | 1 | 2011 | 6 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 21 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 36 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 90 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2011 | 16 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 2011 | 13 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 102 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 910 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 443 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 245 | 0.020 |
Why?
|
| Animals | 1 | 2003 | 9962 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 439 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 245 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 1344 | 0.020 |
Why?
|
| Baltimore | 1 | 2005 | 12 | 0.020 |
Why?
|
| ROC Curve | 1 | 2005 | 139 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 472 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 508 | 0.010 |
Why?
|